SCHEMBL4236100

SCHEMBL4236100

COc1nc(NCCO)nc(OC)c1[N+](=O)[O-]

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
HPGD P15428 1/20 0.51
CDK5 Q00535 3/20 0.50
CDK5R1 Q15078 3/20 0.50
NR1I2 O75469 1/20 0.50
AHR P35869 1/20 0.50
GSK3A P49840 1/20 0.50
GSK3B P49841 1/20 0.50
MAPT P10636 5/20 0.43
TDP1 Q9NUW8 2/20 0.43
KMT2A Q03164 2/20 0.43
LMNA P02545 1/20 0.43
THRB P10828 1/20 0.43
POLB P06746 2/20 0.42
ATM Q13315 1/20 0.42
GAA P10253 2/20 0.42
ABCG2 Q9UNQ0 1/20 0.42
PKM P14618 2/20 0.41
USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4237910 0.84 NR1I2 (0.40) ALDH1A1SMN1; SMN2HPGDCDK5CDK5R1
SCHEMBL14086975 0.82 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2MAPTKMT2APOLB
SCHEMBL4233376 0.82 NR1I2 (0.37) ALDH1A1SMN1; SMN2HPGDCDK5CDK5R1
SCHEMBL4231928 0.82 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2HPGDCDK5CDK5R1
SCHEMBL4231751 0.81 MAPT (0.41) ALDH1A1SMN1; SMN2HPGDCDK5CDK5R1
SCHEMBL4227995 0.81 ALDH1A1 (0.38) ALDH1A1SMN1; SMN2HPGDCDK5CDK5R1
SCHEMBL4227297 0.80 CA1 (0.41) ALDH1A1SMN1; SMN2HPGDCDK5CDK5R1
SCHEMBL4240263 0.79 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2HPGDCDK5CDK5R1
SCHEMBL4231251 0.79 TOP2A (0.41) ALDH1A1SMN1; SMN2HPGDCDK5CDK5R1
SCHEMBL4238515 0.78 MAPT (0.42) ALDH1A1SMN1; SMN2HPGDCDK5CDK5R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209522-A1 Heterocyclic Non-Peptide GNRH Antagonists TAKEDA CAMBRIDGE LIMITED (GB) 2009-08-20 US disclosed
US-20090209522-A1 Heterocyclic Non-Peptide GNRH Antagonists TAKEDA CAMBRIDGE LIMITED (GB) 2009-08-20 US disclosed
EP-1896465-A1 HETEROCYCLIC NON-PEPTIDE GNRH ANTAGONISTS Takeda Cambridge Limited (GB) 2008-03-12 EP disclosed
WO-2007000582-A1 HETEROCYCLIC NON-PEPTIDE GNRH ANTAGONISTS TAKEDA CAMBRIDGE LIMITED (GB) 2007-01-04 WO disclosed
WO-2007000582-A1 HETEROCYCLIC NON-PEPTIDE GNRH ANTAGONISTS TAKEDA CAMBRIDGE LIMITED (GB) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209522-A1 Heterocyclic Non-Peptide GNRH Antagonists GNRHR, GHRHR, FSHR ALDH1A1 4595/4885SMN1; SMN2 3709/4885HPGD 884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.